Prosecution Insights
Last updated: November 04, 2026
Application No. 18/263,732

METHOD FOR PROMOTING ANTIOXIDANT ACTIVITY OF PURPLE TEA LEAVES

Non-Final OA §103§112
Filed
Aug 01, 2023
Priority
Feb 18, 2021 — RE 10-2021-0021691 +1 more
Examiner
CAIN, JENNIFER LYNN
Art Unit
1655
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Cleanbeauty Inc.
OA Round
3 (Non-Final)
44%
Grant Probability
Moderate
3-4
OA Rounds
3m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 44% of resolved cases
44%
Career Allowance Rate
28 granted / 63 resolved
-15.6% vs TC avg
Strong +68% interview lift
Without
With
+68.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
36 currently pending
Career history
116
Total Applications
across all art units

Statute-Specific Performance

§101
8.0%
-32.0% vs TC avg
§103
42.4%
+2.4% vs TC avg
§102
17.6%
-22.4% vs TC avg
§112
23.9%
-16.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 63 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 26 May 2026 has been entered. Claim Status Applicant’s remarks and amendments, filed 26 May 2026 in response to the final rejection mailed 24 February 2026, are acknowledged and have been fully considered. Applicant’s amendments to the claims are acknowledged. The listing of claims filed 26 May 2026 replaces all prior versions and listings of the claims. Claims 5 and 6 are pending. Claim 1 is canceled by Applicant’s amendment. Claim 5 is amended. Claims 5 and 6 are being examined on the merits. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 5 and 6 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The limitation “the purple tea extract is present in a concentration of 0.01 milligrams per milliliter of the water” in Claim 5 is indefinite because it is unclear what is being referenced. In the tables presented on page 2 of the remarks dated 29 December 2025, the extract concentration refers to the concentration of purple tea leaf extract used in the DPPH and ABTS assays. As presented in the current claims, the purple tea leaf extract is the product of the extraction with water, and it is therefore unclear how the water extract can be present in the water from which it is obtained at a particular concentration. Is the concentration meant to refer to the concentration of the extract in the composition, or is the concentration referring to the concentration of roasted purple tea leaves present in the water? The limitation “a purple tea extract obtained by extracting purple tea leaves with water by a method of increasing antioxidant activity” is indefinite because it is unclear what this limitation means. Appropriate clarification is necessary. All other claims depend directly or indirectly from rejected claims and are, therefore, also rejected under 35 U.S.C. §112(b) for the reasons set forth above. Please note, in the interest of advancing prosecution the following proposed phrasing (to Claim 5), is presented for applicant’s consideration, and is considered to be sufficient to overcome the above 112(b) clarity issues if presented (or similar phrasing) in applicant’s response in an amended claim: -- 5. A composition comprising a purple tea extract obtained by: (a) roasting purple tea leaves at a temperature of approximately 140°C; and (b) extracting the roasted purple tea leaves with water at approximately 100°C; wherein the purple tea extract is present in the composition at a concentration of 0.01 mg/mL. -- Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 5 and 6 are rejected under 35 U.S.C. 103 as being unpatentable over Lv et al. (J Funct Food, 2015, 449-458) in view of Mao et al. (Int J Food Sci Tech, 2018, 2586-2594). The instant claims are as of record, drawn to a method of increasing antioxidant activity of purple tea leaves comprising roasting the tea leaves at 140°C and then extracting the roasted tea leaves in water at 100°C. Lv et al. teaches that preparing purple tea leaves using the roasted green tea method (roasting purple tea leaves) maintains anthocyanin levels, antioxidant activity, and sensory quality (active ingredient; Lv et al., 4., page 456; as required for instant Claim 5). The purple tea leaves were prepared using various traditional methods and subsequent tea brewing (antioxidant food composition; as required for instant Claim 6) was conducted using boiled (e.g., 100°C; as required for instant Claim 5) water (Lv et al., 2.3.1.(ii), page 452). The teas prepared using the roasted green tea method were shown to have higher antioxidant activity (increasing the antioxidant activity) compared to other traditional preparation methods (Lv et al., T2 in Figure 4, page 455; as required for instant Claim 1). Lv et al. do not teach the specific roasting temperature of Claim 5, or wherein the concentration of the extract is 0.01 mg/ml. Mao et al. teach that various roasting treatments have different effects upon green tea and that roasting at 140°C for 30 minutes was one method that achieved the most satisfying sensory quality (Mao et al., Summary, page 2586; as required for instant Claim 5). It would have been obvious to a person of ordinary skill in the art prior to the effective filing date of the instant application to utilize the method of Lv et al. to prepare antioxidant-enriched purple tea products using the roasted green tea method of Mao et al. in order to arrive at the instantly claimed invention. A skilled artisan would have a reasonable expectation of success at using the roasting method of Mao et al. because the roasted green tea method used by Lv et al. produced tea with higher antioxidant level and would be motivated to use the roasting temperature taught by Mao et al. because it imparts a satisfying sensory quality for the drinker. A skilled artisan would additionally be motivated to use the method of Mao et al. because increased roasting temperatures reduce the amount of polyphenol content in tea (Mao et al., Figure 1, page 2589), and presence of polyphenols can contribute to reduction in anthocyanin (antioxidant) content (Lv et al., 3.2., page 455). Additionally, based upon the overall beneficial teaching provided by the references with respect to roasting and extraction of in the manner disclosed therein, the adjustments of particular conventional working conditions (e.g., determining one or more suitable concentrations of Claim 5) is deemed merely a matter of judicious selection and routine optimization which is well within the purview of the skilled artisan. From the teachings of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole was prima facie obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary. Please note, since the Office does not have the facilities for examining and comparing Applicants’ composition with the composition of the prior art, the burden is on applicant to show a novel or unobvious difference between the claimed product and the product of the prior art. See In re Best, 562 F.2d 1252, 195 USPQ 430 (CCPA 1977) and In re Fitzgerald, 619 F.2d 67, 205 USPQ 594 (CCPA 1980), and “as a practical matter, the Patent Office is not equipped to manufacture products by the myriad of processes put before it and then obtain prior art products and make physical comparisons therewith.” In re Brown, 459 F.2d 531, 535, 173 USPQ 685, 688 (CCPA 1972). Response to Arguments Applicant's arguments filed 26 May 2026 have been fully considered but they are not persuasive. Regarding the rejection of Claim 5 under 35 USC § 112(b), applicant argues that the specification indicates the concentration of purple tea leaves in the water when the extraction is performed is 5 g / 50 mL (e.g., 100 mg/mL) and that the concentration of the extract used in the assays is 0.01 mg/mL, however this does not clarify the limitation as stated in the claim. As written, it is unclear whether the purple tea extract being present at a concentration of 0.01 mg/mL of the water is referencing the concentration of roasted purple tea leaves present in the water for the extraction step, or whether it is referencing the concentration of the extract in the composition. Regarding the rejections of Claims 5 and 6 under 35 USC § 103, applicant argues that the prior art does not teach a concentration of exactly 0.01 mg/mL of the water, which achieves a functional antioxidant effect. Firstly, it is noted that the instant claims do not recite comparative phrasing which requires increased antioxidant activity relative to other specific extracts. Instead, the claims are merely drawn to a composition which has antioxidant activity that is broadly increased, and based upon the teachings of Mao et al. (at Figure 1(c), pg. 2589), the roasting temperature of 140°C results in increased polyphenol content relative to those roasted at higher temperatures and would therefore have higher antioxidant activity, because presence of polyphenols can contribute to reduction in anthocyanin (antioxidant) content (Lv et al., 3.2., pg. 455). Similarly, applicant argues that there is a 140°C spike in radical scavenging activity relative to an unroasted control, however this element is not recited in the instant claims, as previously discussed. Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See In re Van Geuns, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993). Conclusion No claims are currently allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JENNIFER L CAIN whose telephone number is (703)756-1318. The examiner can normally be reached M-Th 5:00am to 5:00pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Anand Desai can be reached at (571)272-0947. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /J.L.C./Examiner, Art Unit 1655 /AARON J KOSAR/Primary Examiner, Art Unit 1655
Read full office action

Prosecution Timeline

Show 1 earlier event
Sep 30, 2025
Non-Final Rejection mailed — §103, §112
Dec 29, 2025
Response Filed
Feb 24, 2026
Final Rejection mailed — §103, §112
May 20, 2026
Examiner Interview Summary
May 20, 2026
Applicant Interview (Telephonic)
May 26, 2026
Request for Continued Examination
May 28, 2026
Response after Non-Final Action
Sep 23, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12779366
CARNOSIC ACID, CARNOSOL AND ROSMARINIC ACID ISOLATION METHOD
4y 8m to grant Granted Nov 03, 2026
Patent 12778880
SKINCARE COMPOSITION CONTAINING SHATAVARI EXTRACT
3y 1m to grant Granted Nov 03, 2026
Patent 12766177
USE OF CRASSOCEPHALUM RABENS EXTRACT IN THE PREVENTION AND/OR TREATMENT OF FATIGUE AND/OR DEPRESSION
3y 5m to grant Granted Oct 20, 2026
Patent 12758685
ACELLULAR SOFT TISSUE-DERIVED MATRICES AND METHODS FOR PREPARING SAME
1y 7m to grant Granted Oct 13, 2026
Patent 12751924
CAROTENOID PREPARATIONS, PREPARATION METHODS, AND APPLICATION THEREOF
3y 2m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
44%
Grant Probability
99%
With Interview (+68.4%)
3y 6m (~3m remaining)
Median Time to Grant
High
PTA Risk
Based on 63 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month